Turn Therapeutics Inc. (Nasdaq: TTRX) announced the appointment of Dr. Robert Redfield, M.D., former CDC Director, as Senior Advisor of Health Policy and Regulatory Affairs to provide strategic guidance on GX-03, its lead investigational therapy in Phase 2 clinical trials for moderate-to-severe atopic dermatitis.
Key takeaways
Turn Therapeutics appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs on February 17, 2026.
Dr. Redfield will guide clinical development, public health implications, and regulatory positioning of GX-03.
GX-03 is a first-in-class, non-systemic topical inhibitor in Phase 2 clinical trials for atopic dermatitis.
Dr. Redfield served as 18th Director of CDC from 2018 to 2021.
Brad Burnam, CEO, stated Dr. Redfield's guidance will accelerate GX-03's regulatory path.